文献速递妇科产科

晚期上皮性卵巢癌新辅助化疗周期数优化:倾向性评分匹配分析

Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
PubMed 文献 · Gynecol Oncol · 2021-07-24

本研究比较晚期上皮性卵巢癌患者接受≤4个周期与>4个周期新辅助化疗后的生存结局。经2:1倾向性评分匹配后纳入140例(A组≤4周期)和70例(B组>4周期),两组OS和PFS无统计学显著差异,B组额外化疗周期与更高的完全和部分缓解率相关。

要点

  • >4周期新辅助化疗在OS和PFS方面不劣于≤4周期
  • BRCA状态与改善的OS相关(HR=0.41)
  • 残留肿瘤与降低的OS相关(HR=1.93)

核心结论

  • 接受超过4个周期的新辅助化疗在晚期卵巢癌中对OS和PFS无不利影响,且进一步化疗可提高缓解率。

研究设计与样本

  • 回顾性队列研究,纳入III-IV期上皮性卵巢癌接受新辅助化疗后行间歇性减瘤术的患者,A组≤4周期(140例),B组>4周期(70例),采用2:1倾向性评分匹配控制选择偏倚。

主要发现

  • 匹配后基线特征无失衡,BRCA状态与改善的OS相关(HR=0.41;95%CI 0.18-0.92,p=0.032)。
  • 残留肿瘤与降低的OS相关(HR=1.93;95%CI 1.08-3.46,p=0.026)。
  • 两组OS无统计学显著差异(2年OS:A组82.4% vs B组77.1%,p=0.109)。
  • 两组PFS无统计学显著差异(2年PFS:A组29.7% vs B组20.0%,p=0.875)。
  • B组中>4周期化疗与相比3-4周期后更高的完全缓解(12.9%)和部分缓解(34.3%)机会相关。

临床怎么用

  • 对于不适合手术的晚期上皮性卵巢癌患者,新辅助化疗超过4个周期在生存方面未见不利影响,可考虑根据临床反应适当延长化疗周期以增加缓解机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Neoadjuvant chemotherapy and interval debulking surgery are now widely offered in ovarian cancer patients unsuitable for surgery; the number of preoperative NACT cycles to be given is still an issue. Our aim was to compare survival outcomes of patients with advanced ovarian cancer treated with ≤4 or more NACT cycles. METHODS: A cohort of AEOC patients with stage III-IV epithelial OC who underwent NACT followed by IDS was identified. Patients were classified in group A (≤4 cycles) and group B (>4 cycles). Selection bias from the heterogeneity of demographic and clinical characteristics was avoided using propensity score matching (2:1 ratio). RESULTS: 140 (group A) and 70 (group B) patients were included. After the propensity score matching, there were no imbalances in baseline characteristics. BRCA status was associated to improved OS (HR = 0.41; 95%CI 0.18.0.92, p = 0.032) and residual tumor to decreased OS (HR = 1.93; 95%CI 1.08-3.46, p = 0.026). Statistically significant differences were not observed in OS (2-year OS 82.4% for group A versus 77.1% for group B, p = 0.109) and PFS (2-year PFS 29.7% for group A versus 20.0% for group A, p = 0.875). In group B, the administration of >4 cycles was related to an additional chance of achieving complete (12.9%) and partial (34.3%) responses compared to responses after 3-4 cycles. CONCLUSIONS: Receiving more than 4 cycles of NACT is no detrimental in terms of OS and PFS in advanced ovarian cancer. Response rates can increase following further cycles administration.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Marchetti C, Rosati A, De Felice F, et al. Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis. Gynecol Oncol. 2021. PMID: 34312003. doi:10.1016/j.ygyno.2021.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。